• By ICR Secretariat
  • Posted Wednesday, November 20, 2019

NICE ‘OK’ for Sativex in MS

http://www.pharmatimes.com/news/nice_ok_for_sativex_in_ms_1317024

The National Institute for Health and Care Excellence (NICE) has recommended Bayer’s Sativex (delta-9 tetrahydrocannabinol (THC) cannabidiol (CBD)), for spasticity in people with multiple sclerosis (MS).

The cannabis-based medicinal product has been approved within its licensed indication, as the organisation deemed it clinically and cost effective at its current list price. NICE also updated the MS Guideline to state that Sativex should be offered to treat spasticity in people with the disorder.